MOB Share Price Performance
SEK 10.84
1.86 (20.71%)
32.3% undervalued intrinsic discount
SEK 16.00
Fair Value
Price SEK 10.84
AnalystConsensusTarget SEK 16.00
Fair ValueSEK 16.00
Share Pricen/a
Narrative Update • Aug 14
Moberg Pharma AB (publ) Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
MOB Community Narratives
AN
Fair Value
·Fair Value SEK 16 32.3% undervalued intrinsic discount
Norway Expansion And EU Approvals Will Strengthen Future Position
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Moberg Pharma
32.3% undervalued intrinsic discount
Norway Expansion And EU Approvals Will Strengthen Future Position
View narrativeAN
Updated 14 Aug
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
MOB: Expanded Licensing And Upcoming Launches Will Drive Future Upside Potential
Fair Value: SEK 16 32.3% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Moberg Pharma AB (publ) Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Nov 12, 2026
- -0.46
- 62.31%
- -128.96%
- 0%
About MOB
- Founded
- 2006
- Employees
- 5
- CEO
- WebsiteView website
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. It has license agreement with Karo Healthcare for distribution in European market. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.
